All News
Dr Kragsnaes presents counter-intuitive data on the gut microbiome. Faecal microbiota transplant ineffective in treating active peripheral psoriatic arthritis, leading to WORSE outcomes. But maybe this also tells us something? @RheumNow #EULAR2021 Abstr#OP0010 https://t.co/nvDvO4Gfxc
Richard Conway RichardPAConway ( View Tweet)
Promising preclinical data of novel dual BAFF/APRIL inihibitor ALPN-303 re:efficacy & immunomodulatory activity vs TACI-i. Could deplete plasma cell compared to anti-CD20 mAbs in #SLE. Be interesting to see how it’ll fare in future clinical trials #EULAR2021 #OP0039 @RheumNow https://t.co/LnQzO67gwI
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Dr Sanchez-Bilbao presents surprising data that tocilizumab may improve even permanent vision loss in GCA @RheumNow #EULAR2021 Abstr#OP0065 https://t.co/oFGNZ04oKr
Richard Conway RichardPAConway ( View Tweet)
ProDERM OP0008: IVIG 2g/kg q4w for dermatomyositis vs PBO, open-label extension. TIS score responders 78% vs 43%. IVIG great option: Not immunosuppressive and works fast, watch for headache, pyrexia, nausea, risk of VTE. #EULAR2021 @RheumNow https://t.co/m4CEkg3EyC
Eric Dein ejdein1 ( View Tweet)
We know smoking is ass w/ RA. How about passive 🚬? French E3N-EPIC cohort: OP0012. Prospective questionaries of 80,000F, 698 incident cases. ⬆️ risk in passive childhood and adult tobacco exposure. #EULAR2021 @RheumNow 🚭! https://t.co/1Rf0euz3VC
Eric Dein ejdein1 ( View Tweet)
OP0010 at #EULAR2021. FLORA trial: Fecal microbiota transplant as add-on Rx to MTX. Small trial showing time-to-event curves show inferiority to sham but good safety. Fascinating concept exploring gut-joint interaction. @RheumNow. https://t.co/BIOmA5z6vK
Eric Dein ejdein1 ( View Tweet)
Some interesting abstracts at #EULAR2021 today on monitoring GCA with:
- ultrasound
OP0055 https://t.co/0fqLIK5IPV
- PET/CT
OP0069 https://t.co/WQl9VaHR9E
OP0064 https://t.co/w7biFT6qy0
What do you believe is the most accurate measure of true disease activity in GCA? @RheumNow
Links:
David Liew drdavidliew ( View Tweet)
Dr Arnold @Yuz6Yusof present on personalised rituximab retreatment in AAV. Interesting that naive B-cell repopulation at 6 months predicts better sustained response compared to absence @RheumNow #EULAR2021 Abstr#OP0057 https://t.co/cypyQVMeYz
Richard Conway RichardPAConway ( View Tweet)
IVIG pending FDA review for tx of dermatomyositis after ProDERM study. Do you use IVIG for tx of DM?
#EULAR2021 @RheumNow
Robert B Chao, MD doctorRBC ( View Tweet)
ProDERM RCT IVIG in Dermatomyositis
⭐️improved TIS scores compared to pbo
⭐️common AE: headaches, pyrexia, nausea
⭐️serious AE: PE, CVA, DVT
⭐️approved in Europe, pending FDA
Abs#OP0008
#EULAR2021 @RheumNow
Robert B Chao, MD doctorRBC ( View Tweet)
Comparison of disease activity and PROs in AxSpA vs. AxPsA
⭐️AxSpA ⬆️ uveitis and IBD
⭐️AxPsA ⬆️enthesitis and dactylitis
⭐️AxSpA pts ⬆️pain, spinal pain PROs
⭐️Fatigue and work impairment did not differ in AxSpA vs AxPsA
Abs#OP0049 #EULAR2021 @RheumNow https://t.co/wGD6IA5ahb
Robert B Chao, MD doctorRBC ( View Tweet)
@jeffsparks knocking it out of the park presenting our findings on b/tsDMARD associations with COVID-19 outcomes @eular_org @EULAR_Press check out our full paper just published in @ARD_BMJ https://t.co/jcA1LN45R3
Zach Wallace zach_wallace_md ( View Tweet)
Dr Palomäki on influence of MUC5B promotor variant on ILD risk in RA and non-RA. Lifetime risk ILD 14.5% for RA+MUC5B+, 5.2% for RA+MUC5B-, 3.9% RA-MUC5B+ 1.3% RA-MUC5B- @RheumNow #EULAR2021 Abstr#OP0007 https://t.co/BnexQE1Pw9
Richard Conway RichardPAConway ( View Tweet)
Dr Ponte presenting on use of halo sign on TA US to monitor GCA disease activity. Seems good, present and increased in 16/17 (94.1%) cases of first disease relapse @RheumNow #EULAR2021 #AbstrOP0055 https://t.co/T6hKjkb4AT
Richard Conway RichardPAConway ( View Tweet)
Abs#OP0009 presents 8 min web-based video for COVID vax education sent via text message. 76% more likely to get vax. #EULAR2021. @RheumNow. Pts need to hear from their rheumatologists our thoughts on vax, ideally in person, but phone is great outreach https://t.co/aimGBufYpe
Eric Dein ejdein1 ( View Tweet)
Excellent job by @jeffsparks @zach_wallace_md @rheum_covid on Abs#0P0006 at #EULAR2021.
⭐️RTX and JAKi: increased COVID severity, not seen in IL-6 or ABA. Critical findings, but confounding role of co-morbidities/ILD/cancer, esp in RTX patients? @RheumNow
Eric Dein ejdein1 ( View Tweet)
Dr. Tani: Who has trouble tapering below 5mg/d prednisone in SLE
☑️Older patients
☑️High disease activity
☑️Skin and MSK manifestations
☑️Pts treated before 2000.
Try to avoid long-term steroid usage early in the disease course, as it gets harder over time. #EULAR2021, @RheumNow
Eric Dein ejdein1 ( View Tweet)
Excellent talk by @LCalabreseDO on the balance of the immune response!
⭐️Exhausted T cells seen in rheumatic dz, chronic infections, cancers, severe COVID-19
⭐️CPI for treatment of latent infections? CPI for treatment of COVID? 🤔
Abs#OP7137 #EULAR2021 @RheumNow https://t.co/18rvFkpPTx
Robert B Chao, MD doctorRBC ( View Tweet)
Secukinumab effective in AS patients, irrespective of gender
AQUILA 52 week study
⭐️improvement in BASDAI, PGA, severity of depressive mood in both men and women
⭐️women had overall higher disease burden in global functioning and depressive mood
POS0899
#EULAR2021 @RheumNow
Robert B Chao, MD doctorRBC ( View Tweet)
Dr Atienza-Mateo presents abstract #POS0595 on abatacept in RA-ILD. Abatacept surprisingly appeared to be equally good in stabilising FVC and DLCO in both UIP and NSIP patterns in RA-ILD. @RheumNow #EULAR2021 Abstr#POS0595 https://t.co/kHUxWXnaBG
Richard Conway RichardPAConway ( View Tweet)